急性髓系白血病一线诱导方案相关进展  

Advances in first⁃line induction regimens for acute myeloid leukemia

作　　者：马萍 洪鸣[1] MA Ping;HONG Ming(Department of Hematology,the First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China)

机构地区：[1]南京医科大学第一附属医院血液科,江苏南京210029

出　　处：《南京医科大学学报(自然科学版)》2025年第1期139-146,共8页Journal of Nanjing Medical University(Natural Sciences)

基　　金：江苏省人民医院(南京医科大学第一附属医院)临床能力提升工程重大项目(JSPH-MA-2022-1)。

摘　　要：急性髓系白血病(acute myeloid leukemia,AML)是成人急性白血病中最常见的类型。蒽环类药物和阿糖胞苷组成的“3+7”方案自20世纪70年代被确立为AML患者的标准诱导方案。此后,不断有临床研究对一线诱导方案进行改良优化,并研究新方案和标准诱导方案相比,在疗效及安全性方面是否更具优势。文章主要阐述AML一线诱导治疗方案的相关进展及相关分子靶向药物的研究,为临床治疗提供参考。Acute myeloid leukemia(AML)is the most common type of acute leukemia in adults.The“3+7”regimen composed of anthracyclines and cytarabine has been established as the standard induction regimen for AML patients since the 1970 s.Since then,on going clinical studies have focused on optimizing the first-line induction regimen and evaluating whether new regimens have more advantages in terms of efficacy and safety compared to the standard induction regimen.This article mainly describes the progress of first-line induction therapy regimens for AML,and the research of related molecular targeted drugs,so as to provide reference for clinical treatment.

关 键 词：急性髓系白血病 诱导治疗 进展 靶向药物 

分 类 号：R733.71[医药卫生—肿瘤]